ft 23 mar 94 survey pharmaceut 5 research move sharper focu therapeut categori growth world pharmaceut market continu deceler research develop manag forc focus way direct compani r amp effort think r amp spend slow say dr roy vagelo chairman chief execut merck last 15 year r amp grown 14 per cent year love continu longer option group respond new environ reduc number therapeut categori explor admittedli giant group continu cover area dr edward scolnick presid merck research laboratori say research thing therapeut area cost much compani without benefit r amp budget dollar 1bn year 1 800 peopl work discoveri forc concentr effort lead edg area research focus say mr lodewijk de vink presid chief oper offic warner lambert like biotechnolog industri soon talk burn rate pharmaceut compani still look area choos therapeut area investig far easi hardest decis make area explor say dr william scott senior vice presid exploratori drug discoveri research bristol myer squibb like kid go candi store credit card kill focus mani r amp director continu duck difficult decis although claim focus area continu explor cover human diseas r amp director whose research look inflammatori diseas cover diseas divers asthma rheumatoid arthriti inflammatori bowel syndrom choos area cover larg number criteria adopt compani import probabl medic need biolog scienc accord dr scolnick biolog understand basic physiolog diseas mechan find project right combin scientif understand medic need set work dr takao tanakaya execut director drug discoveri divis fujisawa agre understand basic patholog diseas although alzheim look interest huge potenti market steer clear dementia understand go mean difficult develop anyth realli innov compani also tri match unmet need expertis schere plough manag work area match compani strength group suffici critic mass make differ accord dr robert spiegel senior vice presid clinic research demand new treatment diseas elderli osteoporosi alzheim attract mani compani dr teruhisa noguchi execut vice presid r amp yamanouchi explain decid concentr cardiovascular gastro intestin central nervou system diseas well endocrinolog diabet bone disord link age popul real problem japan danger focus untreat unexplor area group see need balanc risk differ therapeut categori dr spiegel schere plough explain discoveri area quit comfort invest money patienc product come other high risk area scientif excit could great potenti yield hit right problem new area realli difficult say dr spiegel brand new field regulatori clinic environ unknown take alzheim park davi cognex approv nobodi knew sort efficaci fda want never drug approv area balanc risk number compani cut number therapeut area meaning way smithklin beecham exit gastro intestin diseas 12 month ago area virtual creat predecessor smithklin french probabl dramat howev wellcom also move tropic diseas dr trevor jone director research develop medic say group stop develop new anaesthet complet present gener product dr pierr simon r amp director elf sanofi explain compani decis concentr three area seven year ago sanofi present area research told chairman stupid effect develop becom sophist expens instead decid concentr three area dr leon rosenberg presid bristol myer squibb pharmaceut research institut say cut area next year scale back cardiovascular oncolog major posit dermatolog also stake futur immunolog area central nervou system diseas diagnost cannot lead bright light shine everyth concentr area leader greatest strength therapeut area chosen r amp director next difficulti decid mani compound compet limit develop resourc select last pursu new therapi produc clear medic benefit develop distinct advantag say dr paul herrl head research sandoz much scrutini use qualiti drug develop agre dr robert spiegel senior vice presid clinic research schere plough look market bear product minor improv medicin add valu otherwis prepar spend time money say sir richard syke chief execut glaxo dr scolnick agre uniqu discoveri otherwis end sell gener drug dr simon add recent cut beta blocker h2 antagonist pipelin even though safe effect made sens littl better exist therapi say similarli rhone poulenc rorer last year cut safe effect 5ht 3 antagonist similar glaxo highli success zofran better exist compound accord mr robert cawthorn chief execut group abandon even promis innov project howev dr simon elf sanofi explain use biochem screen come interest compound fit exactli area want work came good asthma drug intent get asthma want licens problem one time talk earli much say late lose time good clinic trial show good sell quickli r amp director agre far easier develop good qualiti drug poor one dr masaji ohno manag director r amp eisai agre chairman mr yuji naito ask us find compound good develop sanofi dr simon add set high standard get compound develop look strength oral activ durat action toxicolog genotox also make sure molecul metabolis man drug clear bar even set high product cost also import issu accord dr herrl look complic molecul mani step take synthesis cost complex manufactur becom much import say dr stephen carter senior vice presid worldwid clinic research develop bristol myer squibb agre go take 15 chemic step produc compound might need 20 chemist full time work year gener enough clinic trial case might put develop potenti market drug also clearli import dr noguchi yamanouchi say compani set target minimum annual sale y2bn dollar 200m drug move develop one consequ new cost consciou environ decis futur molecul made much earlier recent discontinu coupl compound earlier time would continu see happen today luxuri say dr spiegel schere plough howev although compani pay lip servic ride drive toward innov r amp director admit need balanc portfolio risk japan low risk low reward compound call surviv drug accord dr masaji ohno manag director r amp eisai let honest agre dr carter bristol myer squibb go high risk high reward blockbust go home run necessarili good busi singl doubl support franchis need balanc across franchis across risk dollar 100m product old franchis valuabl dollar 150m product new area compani admit set creat drug howev dr spiegel admit set find someth excit sometim come drug offer margin improv import area littl stress r amp director publicli line extens call process evergreen say dr john niblack presid pfizer central research dr carter bristol myer squibb agre line extens help qualiti life gener increas exclus compani besid develop line extens easier develop new compound safeti alreadi proven show efficaci spend lot money worthwhil